Introduction {#Sec1}
============

Leucine (Leu) is an essential amino acid that serves as one of the basic substrates for the synthesis of proteins and polypeptides. In addition, accumulating evidence has shown that Leu plays crucial signaling roles in regulating a wide range of physiological and pathological processes such as satiety^[@CR1],\ [@CR2]^, autophagy^[@CR3],\ [@CR4]^, energy homeostasis and insulin secretion^[@CR5]^. Moreover, as a vital nutrient, Leu and its metabolites also affect the metabolism of other nutrients including carbohydrate, protein (amino acids), and lipid in various types of cells including hepatocytes^[@CR6]^. Previously, a number of studies have demonstrated that Leu reduces lipid accumulation by promoting the oxidation of Leu in either myocytes or adipocytes^[@CR7],\ [@CR8]^. In isolated hepatocytes, however, the case may be different mainly due to the absence of the key enzyme mitochondrial branched-chain amino acid transaminase that catalyzes the first step for the Leu oxidation pathway^[@CR6],\ [@CR9]^. It has been observed that the triglyceride content increases with Leu supplementation in both hepatocytes and hepatoma carcinoma cells^[@CR10],\ [@CR11]^. However, the mechanisms underlying the role of Leu in regulating hepatic lipid metabolism are poorly understood.

Over the past years, several 2-dimensional gel electrophoresis (2-DE) based comparative proteomics strategies have been applied into the functional exploration of specific amino acids including arginine (Arg)^[@CR12]^, glutamine (Gln)^[@CR13],\ [@CR14]^ and methionine (Met)^[@CR15]^. For instance, coupling 2-DE with MALDI-TOF-MS, Lenaerts and co-workers^[@CR12]^ studied the proteome characters of preconfluent or postconfluent Caco-2 cells treated with Arg deficiency and they found that several crucial proteins, such as the cellular apoptosis susceptibility proteins CAS and HSF, and cell proliferation related protein SET, were differentially regulated by Arg deprivation, thus providing a molecular insight into the effects of Arg on cellular proliferation and apoptosis. Deniel *et al*.^[@CR14]^ investigated the effect of Gln on the proteome of human epithelial intestinal cell line HCT-8 dealing with apoptotic conditions, and they found that Gln altered the expressions of crucial apoptotic process related proteins including MAP3K7, Aven, Atg5, and stathmin, thus giving multiple hypotheses regarding to the anti-apoptosis capacities of Gln. Xin and colleagues^[@CR15]^ investigated the effects of Met restriction on the proteome of gastric cancer cells SGC7901 by culturing cells in normal and Met-deprived homocysteine-supplemented media. They identified a total of ten proteins, which are related to cell cycle arrest and apoptosis, that were differentially regulated by Met restriction. These findings give us a more comprehensive understanding of the functionality of specific amino acids. However, due to the limited identification capacity of 2-DE based proteomics strategies^[@CR16]^, the integral effect of specific amino acids on certain cells remains largely unknown.

Since its development in 2004, the isobaric tags for relative and absolute quantification (iTRAQ) technique has become a powerful tool in comparative proteomics field due to several unique advantages including high-throughput, high sensitivity, and great accuracy^[@CR17],\ [@CR18]^. Previously, using the iTRAQ-based approach, we have characterized the proteome of HepG2 cells treated with either Gln deprivation or Arg supplementation^[@CR19],\ [@CR20]^. However, to our knowledge, there is no literature reporting proteome scale alterations induced by Leu deprivation in liver cells. Here, we conducted an iTRAQ-based proteomics study to profile the proteome of Leu-deprived HepG2 cells (Fig. [1A](#Fig1){ref-type="fig"}). Our bioinformatics analysis suggested that Leu deprivation regulated the expressions of proteins that are involved in several crucial biological processes such as amino acid metabolism and lipid metabolism. Simultaneously, our pathway analysis together with the validation assays indicated that the fatty acid β-oxidation pathway was significantly activated by Leu deprivation in HepG2 cells. The present study suggests a potential regulatory role of Leu on fatty acid metabolism in HepG2 cells.Figure 1Identification of the differentially expressed proteins by the iTRAQ-based strategy. (**A**) Schematic diagram of the workflow for the iTRAQ-based experiments. Six dishes of HepG2 cells were pooled into one sample for either normal (Ctrl) or Leu-deprived (-Leu) HepG2 cells. Then pooled cells were fractionated, digested into peptides, labeled with different iTRAQ reagents containing reporter groups of different masses (113, 114), balance groups of different masses (192, 191), and a reactive group (R). The labeled peptides were then mixed equivalently, fractionated by strong cation exchange (SCX), and analyzed by LC-MS/MS. Two independent biological replicates were performed for the iTRAQ experiments. (**B**) The protein distribution in accordance to Log~10~ theoretical weight (MW; Da) versus log~2~ Ratio of all the differentially expressed proteins in -Leu/Ctrl. Red dots indicate up-regulated proteins, green dots indicate down-regulated. (**C**) Validation of the differential expressions of ADH1C and ALDH1A1 by immunoblotting. (**D,E**) Quantitation of ADH1C/β-Actin and ALDH1A1/β-Actin as described in (**C**). Data are means ± SD (n = 3). ^\*^ *P* \< 0.05, ^\*\*^ *P* \< 0.01 (paired Student's *t*-test).

Results {#Sec2}
=======

Quantitative proteomic analysis of HepG2 cells treated with Leu deprivation {#Sec3}
---------------------------------------------------------------------------

By the iTRAQ-coupled LC-MS/MS analysis, a total of 4,111 proteins were quantified between Ctrl and -Leu in the two sets of biological replicates (Supplementary Fig. [S1](#MOESM1){ref-type="media"}). Using a stringent criteria of unique peptide \>1, *P*-value \< 0.05, fold change \>1.2 (or \<0.833) in both the two sets of iTRAQ experiments, we identified 5 differentially expressed proteins for the -Leu/Ctrl (Table [1](#Tab1){ref-type="table"}). In addition, due to the large variation between different iTRAQ runs (Supplementary Fig. [S2](#MOESM1){ref-type="media"}), and to identify more proteins that were potentially regulated by Leu deprivation, we used a less stringent strategy with the criteria of unique peptide \>1, *P*-value \< 0.05, fold change \>2 (or \<0.5) in any one set of the two iTRAQ experiments (similar strategy was performed in refs [@CR19], [@CR21]). By this strategy, 38 proteins were further identified as differentially expressed proteins (Table [1](#Tab1){ref-type="table"}). Thus, there were a total of 43 proteins were finally considered as differentially expressed proteins for the -Leu/Ctrl (Table [1](#Tab1){ref-type="table"}). Out of these proteins, 37 were up-regulated and 6 were down-regulated (Fig. [1B](#Fig1){ref-type="fig"}). In order to validate the differential expressions of proteins derived from the iTRAQ experiments, we immunoblotted two proteins alcohol dehydrogenase 1 C (ADH1C) and retinal dehydrogenase 1 (ALDH1A1; Fig. [1C](#Fig1){ref-type="fig"}). The selection of these two proteins was due to their potential correlation with the function of specific amino acid^[@CR19]^, and the relative expressions of these proteins between Ctrl and -Leu groups were consistent with those determined by the iTRAQ approach (Fig. [1D,E](#Fig1){ref-type="fig"}).Table 1All the differentially expressed proteins identified by the iTRAQ experiments.AccessionDescriptionGene name-Leu/Ctrl (Set1\|Set2)-Leu/Ctrl used for analysisProteins identified by the stringent criteria of unique peptide \>1, *P*-value \< 0.05, fold change \>1.2 (or \<0.833) in both the two sets of iTRAQ experiments Q86U79Adenosine kinase*ADK*1.969\*\|1.376\*1.673 P57081tRNA (guanine-N(7)-)-methyltransferase non-catalytic subunit WDR4*WDR4*0.830\*\|0.810\*0.820 Q9UNS1Protein timeless homolog*TIMELESS*0.739\*\|0.773\*0.756 P04264Keratin, type II cytoskeletal 1*KRT1*0.776\*\|0.609\*0.693 P13645Keratin, type I cytoskeletal 10*KRT10*0.544\*\|0.567\*0.556Proteins identified by the less stringent criteria of unique peptide \>1, *P*-value \< 0.05, fold change \>2 (or \<0.5) in any one set of the two iTRAQ experiments Q15493Regucalcin*RGN*12.059\*\|-12.059 Q9H2A2Aldehyde dehydrogenase family 8 member A1*ALDH8A1*11.577\*\|-11.577 P00439Phenylalanine-4-hydroxylase*PAH*11.075\*\|-11.075 A5YKK6CCR4-NOT transcription complex subunit 1*CNOT1*7.806\*\|-7.806 Q93088Betaine--homocysteine S-methyltransferase 1*BHMT*7.652\*\|-7.652 P52758Ribonuclease UK114*HRSP12*6.583\*\|-6.583 P05166Propionyl-CoA carboxylase beta chain, mitochondrial*PCCB*6.541\*\|-6.541 B3VL17Beta globin (Fragment)*HBB*6.408\*\|-6.408 Q3KPF3Cytochrome P450, family 2, subfamily D, polypeptide 6*CYP2D6*6.326\*\|-6.326 P00326Alcohol dehydrogenase 1 C*ADH1C*6.317\*\|-6.317 Q9UI17Dimethylglycine dehydrogenase, mitochondrial*DMGDH*5.834\*\|-5.834 O75367Core histone macro-H2A.1*H2AFY*5.740\*\|-5.740 P33121Long-chain-fatty-acid--CoA ligase 1*ACSL1*5.621\*\|-5.621 P30038Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial*ALDH4A1*5.152\*\|-5.152 P00480Ornithine carbamoyltransferase, mitochondrial*OTC*4.747\*\|-4.747 D4QEZ8Short-chain acyl-CoA dehydrogenase*ACADS*4.739\*\|-4.739 Q9Y365PCTP-like protein*STARD10*4.659\*\|-4.659 B2RBJ5Alanine-glyoxylate aminotransferase 2 (AGXT2), nuclear gene encoding mitochondrial protein*AGXT2*3.959\*\|-3.959 P83111Serine beta-lactamase-like protein LACTB, mitochondrial*LACTB*3.667\*\|-3.667 P00352Retinal dehydrogenase 1*ALDH1A1*3.423\*\|-3.423 P21695Glycerol-3-phosphate dehydrogenase \[NAD(+)\], cytoplasmic*GPD1*3.393\*\|-3.393 P47989Xanthine dehydrogenase/oxidase*XDH*3.342\*\|-3.342 Q3SY69Mitochondrial 10-formyltetrahydrofolate dehydrogenase*ALDH1L2*3.299\*\|-3.299 Q16696Cytochrome P450 2A13*CYP2A13*2.950\*\|-2.950 P26440Isovaleryl-CoA dehydrogenase, mitochondrial*IVD*2.722\*\|-2.722Q3LXA3Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing)*DAK*2.606\*\|-2.606 P42357Histidine ammonia-lyase*HAL*2.559\*\|-2.559 O14975Very long-chain acyl-CoA synthetase*SLC27A2*2.343\*\|-2.343 P07858Cathepsin B*CTSB*2.212\*\|-2.212 P62879Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2*GNB2*2.207\*\|-2.207 P09417Dihydropteridine reductase*QDPR*2.140\*\|-2.140 Q16134Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial*ETFDH*2.090\*\|-2.090 P09455Retinol-binding protein 1*RBP1*2.087\*\|-2.087 P60953Cell division control protein 42 homolog*CDC42*2.032\*\|-2.032 P32189Glycerol kinase*GK*2.009\*\|-2.009 P61916Epididymal secretory protein E1*NPC2*2.005\*\|-2.005 Q562E7WD repeat-containing protein 81*WDR81*0.311\*\|-0.311 Q8N201Integrator complex subunit 1*INTS1*0.292\*\|-0.292^\*^ *P* \< 0.05.

Subcellular and functional characterization of the differentially expressed proteins {#Sec4}
------------------------------------------------------------------------------------

We next catalogued the subcellular annotation of all the differentially expressed proteins. Based on the Gene Ontology (GO), the differentially expressed proteins were found to mainly localize to mitochondrion, cytosol, membrane, and nucleus (Fig. [2](#Fig2){ref-type="fig"}).Figure 2GO subcellular annotation for all the differentially expressed proteins in Leu-deprived HepG2 cells. Horizontal axis indicates the actual number of differentially expressed protein annotated in certain compartment.

To characterize the functional roles and biological processes of the differentially expressed proteins after the treatment of Leu deprivation, the protein Uniprot accessions and ratios of -Leu/Ctrl were uploaded into the Ingenuity Pathway Analysis (IPA) software in which the differentially regulated proteins were all characterized with statistical significance (*P* \< 0.05)^[@CR22]^. Based on the functional characterization in IPA, we showed three functional settings into which all the uploaded proteins were classified: molecular and cellular functions, physiological system development and functions, and hepatotoxicity. The differentially expressed proteins were shown to be involved in various biological processes (Supplementary Table [S1](#MOESM1){ref-type="media"}), such as "Amino Acid Metabolism" and "Lipid Metabolism" (Fig. [3A](#Fig3){ref-type="fig"}), "Tissue Morphology" (Fig. [3B](#Fig3){ref-type="fig"}), and "Liver Steatosis" (Fig. [3C](#Fig3){ref-type="fig"}).Figure 3Functional characterization of the differentially expressed proteins in -Leu/Ctrl. (**A**) Molecular and cellular functions. (**B**) Physiological system development and functions. (**C**) Hepatotoxicity. More information is available in Supplementary Table [S1](#MOESM1){ref-type="media"}.

Amino acid metabolism was altered by Leu deprivation in HepG2 cells {#Sec5}
-------------------------------------------------------------------

To test whether the metabolism of other amino acids was affected by Leu deprivation in HepG2 cells, we classified the amino acid metabolism-related differentially expressed proteins. We found amino acid metabolism was significantly altered in -Leu/Ctrl based on the function characterization of IPA analysis (Fig. [3A](#Fig3){ref-type="fig"}). A total of 11 differentially expressed proteins, such as betanine--homocysteine S-methyltransferase 1 (BHMT), and mitochondrial ornithine carbamoyltransferase (OTC), are involved in various amino acid metabolic pathways including cysteine and methionine metabolism, arginine and proline metabolism (Table [2](#Tab2){ref-type="table"}).Table 2All the amino acid metabolism-related differentially expressed proteins.AcessionDescriptionGene Name-Leu/CtrlAmino acid metabolism processQ9H2A2Aldehyde dehydrogenase family 8 member A1*ALDH8A1*11.577\*Val, Leu and Ile degradation; β-Ala metabolism; Arg and Pro metabolism; His metabolism; Lys degradationP00439Phenylalanine-4-hydroxylase*PAH*11.075\*Phe, Tyr and Trp biosynthesisQ93088Betaine--homocysteine S-methyltransferase 1*BHMT*7.652\*Gly, Ser and Thr metabolism; Cys and Met metabolismP05166Propionyl-CoA carboxylase beta chain, mitochondrial*PCCB*6.541\*Val, Leu and Ile degradationQ9UI17Dimethylglycine dehydrogenase, mitochondrial*DMGDH*5.834\*Gly, Ser and Thr metabolismP30038Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial*ALDH4A1*5.152\*Arg and Pro metabolism; Ala, Asp and Glu metabolismP00480Ornithine carbamoyltransferase, mitochondrial*OTC*4.747\*Arg and Pro metabolismD4QEZ8Short-chain acyl-CoA dehydrogenase*ACADS*4.739\*Val, Leu and Ile degradationB2RBJ5Alanine-glyoxylate aminotransferase 2*AGXT2*3.959\*Gly, Ser and Thr metabolism; Ala, Asp and Glu metabolismP26440Isovaleryl-CoA dehydrogenase, mitochondrial*IVD*2.722\*Val, Leu and Ile degradationP42357Histidine ammonia-lyase*HAL*2.559\*His metabolism^\*^ *P* \< 0.05. Val, valine; Leu, leucine; Ile, isoleucine; Ala, alanine; Arg, arginine; Pro, proline; His, histidine; Lys, lysine; Phe, phenylalanine; Tyr, tyrosine; Trp, tryptophan; Gly, glycine; Ser, serine; Thr, threonine; Cys, cysteine; Met, methionine; Asp, aspartate; Glu, glutamate.

Leu deprivation leads to the activation of fatty acid β-oxidation pathway in HepG2 cells {#Sec6}
----------------------------------------------------------------------------------------

Many proteins can only be effective through interacting with their partner(s)^[@CR23]^, the exploration of interacting relationships among all the differentially expressed proteins is crucial to understand the integral biological role of relevant proteins upon certain treatment. Thus, we also performed the network analysis using the IPA tool, in which the interaction annotation is based on the microarray results of numerous publications^[@CR24]^. Based on the scores, the network "Drug Metabolism, Lipid Metabolism, Small Molecule Biochemistry" was highly enriched in -Leu/Ctrl (Score 53; Fig. [4A](#Fig4){ref-type="fig"}). Combined with the functional characterization result (Fig. [3A](#Fig3){ref-type="fig"}), the interaction network analysis suggested the lipid metabolism might be altered by Leu deprivation in HepG2 cells. Interestingly, further analysis of the signaling pathways altered by Leu deprivation suggested several lipid metabolism-related metabolic pathways, particularly fatty acid metabolic pathways, including "Fatty Acid β-Oxidation I" (*P* = 3.74e^−05^), were significantly altered upon Leu deprivation (Fig. [4B](#Fig4){ref-type="fig"}). Two proteins long-chain-fatty-acid--CoA ligase 1 (ACSL1, 5.621-fold), and short-chain acyl-CoA dehydrogenase (ACADS, 4.739-fold), which are the key enzymes involved in the fatty acid β-oxidation pathway (Supplementary Fig. [S3](#MOESM1){ref-type="media"}), were significantly up-regulated by Leu deprivation. In addition, the protein peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), which also plays crucial role in the fatty acid β-oxidation, was likely up-regulated (1.462-fold) by Leu deprivation (Supplementary Fig. [S3](#MOESM1){ref-type="media"}). To validate the LC-MS/MS data and confirm whether the fatty acid β-oxidation pathway was altered by Leu deprivation, we compared the ratios of ACSL1, ACADS, and ACOX1 between the Ctrl and -Leu by immunoblotting (Fig. [4C](#Fig4){ref-type="fig"}). The expressions of these three proteins were conformity with those determined by the iTRAQ labeled LC-MS/MS strategy (Fig. [4D--F](#Fig4){ref-type="fig"}). In addition, the cellular lipid content and accumulation were reduced by Leu deprivation in HepG2 cells (Fig. [4G,H](#Fig4){ref-type="fig"}). These results suggest that Leu deprivation leads to the activation of the fatty acid β-oxidation pathway in HepG2 cells.Figure 4Leu deprivation activates the fatty acid β-oxidation pathway in HepG2 cells. (**A**) The most enriched interaction network of the differentially expressed proteins in Leu-deprived HepG2 cells. Red indicates up-regulated; green indicates down-regulated; white indicates proteins involved in certain network but not differentially expressed in this study. The degree of change for protein expression is indicated by color depth. (**B**) The 20 top canonical pathways ranked by the *P*-values in the IPA tools for the -Leu/Ctrl. (**C**) Immunoblotting of ACSL1, ACADS, ACOX1, and β-Actin in the HepG2 cells treated with Leu deprivation as indicated. (**D--F**) Quantitation of ACSL1/β-Actin, ACADS/β-Actin, and ACOX1/β-Actin as described in (**C**). Data are means ± SD (n = 3). ^\*^ *P* \< 0.05 (paired Student's *t*-test). (**G**) HepG2 cells were cultured with normal and Leu-deprived media for 24 hours, then cells were stained with ORO and observed with a microscope at 40x magnification. Representative images were shown. (**H**) Cellular TG content was measured in HepG2 cells with different treatments as described in (**G**). Data are means ± SD (n = 6). ^\*\*\*^ *P* \< 0.001 (unpaired Student's *t*-test).

Discussion {#Sec7}
==========

In the present study, we for the first time comparatively characterized the proteome alteration induced by Leu deprivation in HepG2 cells using iTRAQ-coupled LC-MS/MS analysis. One of our major findings was that the fatty acid β-oxidation pathway was activated by Leu deprivation in HepG2 cells. Lipid metabolism, including fatty acid metabolism, is a primary function of the liver. In hepatocytes, excessive free fatty acids are incorporated into triglycerides that can then be stored in lipid droplets^[@CR25]^, the lipid droplets will be degraded to produce fatty acids under nutrient deficiency conditions to maintain cellular energy homeostasis through the β-oxidation of fatty acids^[@CR25],\ [@CR26]^, a main energy-generating process that involves a series of proteins^[@CR27]^. Among these proteins, ACSL1, which is highly expressed in liver^[@CR28]^, is a vital enzyme that belongs to the class of acyl-CoA synthetases which are essential for the anabolism of lipid, and catabolism of fatty acids^[@CR29]^. In hepatocytes, ACSL1 converts long-chain fatty acids into activated acyl-CoA, and the activated acyl-CoA then enters the β-oxidation pathway for producing energy^[@CR29],\ [@CR30]^. Decreases in ACSL1 activity significantly decreases triglyceride synthesis and fatty acid β-oxidation in hepatocytes or livers^[@CR31]^. Additionally, ACADS, another crucial enzyme for the β-oxidation of fatty acids, catalyzes the first step of mitochondrial short-chain fatty acid β-oxidation^[@CR32]^. Meanwhile, ACOX1 acts as the rate-limiting enzyme in the peroxisomal fatty acid β-oxidation pathway, another mechanism for fatty acid β-oxidation^[@CR33],\ [@CR34]^. In the present study, our iTRAQ data together with immunoblotting assays demonstrated that ACSL1, ACADS, and ACOX1 were highly up-regulated by Leu deprivation in HepG2 cells. Furthermore, we also found the cellular triglycerides were reduced by Leu deprivation in HepG2 cells, which might be partially caused by the activation of fatty acid β-oxidation pathway. Previously, a number of studies have demonstrated that Leu affects the content of cellular triglycerides in hepatocytes or livers. For instance, Guo and Cavener^[@CR10]^ reported that dietary Leu deprivation down-regulated the fatty acid synthesis-related genes, thus leading to the reduction of triglycerides in mouse livers. In addition, Zarfeshani *et al*.^[@CR11]^ recently showed the cellular triglycerides were accumulated upon 0.1 mM and 2.5 mM Leu supplementation in HepG2 cells. However, most of the related studies did not explore the connection between Leu deprivation/supplementation with the oxidation of fatty acids, which is also a main contributor for the cellular lipid content. Our finding thus suggests a new way for the regulation of lipid metabolism through the oxidation of fatty acids caused by Leu in hepatocytes. While the mechanism by which Leu deprivation activates hepatic fatty acid β-oxidation remains elusive, a possible explanation is that Leu deprivation might up-regulate several upstream transcription factors with transcriptional control over the lipid (fatty acid) metabolism genes. In support of this notion, our upstream analysis showed that the peroxisome proliferator-activated receptor (PPAR) family core members, PPAR-γ and PPAR-α, which both transcriptionally regulate *ACSL1* and *ACADS*, were predicated to be activated in Leu-deprived HepG2 cells (Supplementary Fig. [S4](#MOESM1){ref-type="media"}).

In addition, our bioinformatics analysis showed that global amino acid metabolism was significantly altered by Leu deprivation (Fig. [3A](#Fig3){ref-type="fig"}). Also, we identified 11 differentially expressed proteins that are involved in amino acid metabolism (Table [2](#Tab2){ref-type="table"}). Among these, the proteins aldehyde dehydrogenase family 8 member A1 (ALDH8A1), mitochondrial delta-1-pyrroline-5-carboxylate dehydrogenase (ALDH4A1), mitochondrial ornithine carbamoyltransferase (OTC), are involved in the metabolism of Arg. The protein OTC is a key involver of hepatic urea cycle pathway^[@CR35],\ [@CR36]^, in which Arg is a direct precursor for the production of urea^[@CR36]^. The up-regulation of OTC suggested that the urea cycle might be activated by Leu deprivation, which was consistent with several previous studies^[@CR37],\ [@CR38]^. Interestingly, two controversial explanations were raised about the site of Leu affecting urea cycle: at glutamate dehydrogenase^[@CR39]^ or at OTC^[@CR37]^. Obviously, our result supported that the OTC is more likely the site since we found no differential expression of glutamate dehydrogenase after Leu deprivation in HepG2 cells. Together, our data suggested that Leu deprivation might promote the conversion of Arg into urea by up-regulating OTC, showing a potential way for Leu regulating Arg metabolism in HepG2 cells.

Also, our iTRAQ data together with pathway analysis have shown a number of crucial proteins were significantly regulated by Leu deprivation. The present study showed that two proteins ADH1C and ALDH1A1, which are the key enzymes in ethanol degradation pathways, were up-regulated by Leu deprivation in our iTRAQ data. Moreover, the differential expressions of these proteins were further validated by the immunoblotting assays. Once reaching to the cytosol of liver cells, which is the main site for the degradation of ethanol, ethanol will be converted to acetaldehyde by ADH^[@CR40]^. The acetaldehyde, a highly toxic substance that causes multiple malfunctions in organism^[@CR41],\ [@CR42]^, will then be catalyzed into acetate by the ALDH^[@CR40],\ [@CR43]^. Previously, a number of studies have demonstrated that ethanol oxidation can be accelerated by specific amino acids. Tanaka *et al*.^[@CR44]^ found that Ala could accelerate ethanol oxidation in the livers of rats treated with acute ethanol. And our previous research has found that the ethanol degradation pathways were activated upon the supplementation of another functional amino acid, Arg, in HepG2 cells^[@CR19]^. Since the metabolism of amino acids can be affected by each other (also shown in this study), it is possible that, besides Ala and Arg, other amino acid(s) may also function in the ethanol degradation pathways. Our finding for the first time showed that Leu deprivation activated the ethanol degradation pathways, thus extended the idea that specific AAs (at least including Ala, Arg, and Leu) may have roles in ethanol metabolism in HepG2 cells. While needed to be further validated in other hepatocyte-derived cell lines as well as *in vivo* trials, this finding provides new insight into the role of Leu in attenuating the malfunction induced by acute or chronic exposure of ethanol in the liver.

In conclusion, by coupling iTRAQ with LC-MS/MS, we for the first time investigated the proteome response to Leu deprivation in HepG2 cells. Our data have shown that the cellular amino acid metabolism was significantly altered by the Leu treatment. Importantly, we found that Leu deprivation disturbed some biological processes that have not been connected with Leu treatments before, particularly the fatty acid β-oxidation pathway. Although this phenomenon needs to be further investigated in other liver cell lines as well as animal trials, our findings provide new insights into the regulation of fatty acid metabolism by specific amino acids, especially Leu in the HepG2 cell line.

Materials and Methods {#Sec8}
=====================

Cell line and culture {#Sec9}
---------------------

The human hepatocellular carcinoma (HepG2) cell line, which is a hepatocyte-derived cell line and has been widely used as an *in vitro* hepatocyte model (e.g., see refs [@CR45]--[@CR47]), was a kind gift from Dr. Zaiqing Yang (Huazhong Agricultural University, College of Life Science and Technology). HepG2 cells were grown in RPMI-1640 (11875, Gibco) supplemented with 10% fetal bovine serum (1660516, Gibco) and 1% penicillin-streptomycin (15070, Invitrogen). To produce the Leu-deprived medium, RPMI-1640 without leucine, arginine, and lysine (R1780, Sigma-Aldrich) was supplemented with 200 mg/L (final concentration) arginine (0953, Amresco), 40 mg/L (final concentration) lysine (M234, Amresco), 10% fetal bovine serum and 1% penicillin-streptomycin. When cells were grown to approximately 80% confluence, twelve dishes of cells were randomly divided into two groups treated as follows: 1) for normal group (Ctrl), six dishes of HepG2 cells were cultured in fresh complete medium for 50 min; 2) for Leu deprivation group (-Leu), six dishes of HepG2 cells were cultured in Leu-deprived medium for 50 min. All the cell cultures were performed at 37 °C under 5% CO~2~. For iTRAQ experiments, two independent biological replicates were performed to increase the statistical confidence.

Protein preparation and digestion, iTRAQ labeling {#Sec10}
-------------------------------------------------

Six dishes of harvested HepG2 cells for each group were pooled into one sample to reduce the individual error as previously described^[@CR19]^. The pooled cells were then lysed with the buffer (7 M Urea, 2 M Thiourea, 4% CHAPS, 40 mM Tris-HCl, pH 8.5, 1 mM PMSF, 2 mM EDTA) and sonicated in ice. The total proteins were reduced with 10 mM DTT at 56 °C for 1 h, alkylated with 55 mM IAM in the darkroom for 1 h, and precipitated by adding 4 × volume of chilled acetone at −20 °C overnight. Then the samples were centrifuged at 4 °C, 30,000 g. The pellet was dissolved in 0.5 M TEAB (Applied Biosystems, Milan, Italy) and sonicated in ice. After centrifuged at 4 °C, 30,000 g, the protein concentration of supernatant was determined of by Bradford essay. Approximately 100 μg of total protein was digested with trypsin to protein ratio of 30:1 at 37 °C for 16 h. The digested peptides were dried by vacuum centrifugation, reconstituted in 0.5 M TEAB and processed according to the manufacture's protocol (Applied Biosystems). Samples were labeled with the iTRAQ reagents below: Ctrl (tag 113) and -Leu (tag 114). The labeled peptides were then incubated at room temperature for 2 h and vacuum-dried.

Strong cation exchange (SCX) chromatography {#Sec11}
-------------------------------------------

SCX chromatography was carried out to remove all interfering substances with an LC-20AB HPLC Pump system (Shimadzu, Kyoto, Japan). The labeled peptide mixtures were reconstituted with 4 mL buffer A (25 mM NaH~2~PO~4~ in 25% acetonitrile, pH 2.7) and loaded onto a 4.6 × 250 mm Ultremex SCX column containing 5-μm particles (Phenomenex). The peptides were eluted at a flow rate of 1 mL/min with a gradient of buffer A for 10 min, 5--60% buffer B (25 mM NaH~2~PO~4~, 1 M KCl in 25% acetonitrile, pH 2.7) for 27 min, 60--100% buffer B for 1 min, and then maintained at 100% buffer B for 1 min, equilibrated with buffer A for 10 min. The eluted peptides were collected every 1 min and pooled into 20 fractions, desalted using a Strata X C18 column (Phenomenex) and vacuum-dried.

LC-ESI-MS/MS analysis based on Q EXACTIVE {#Sec12}
-----------------------------------------

The Q EXACTIVE based LC-ESI-MS/MS was performed as previously described with minor modifications^[@CR48]^. Fractions were re-suspended in solvent A (2% acetonitrile, 0.1% formic acid) and centrifuged at 20,000 g for 10 min. Then, 5 μg of peptide mixture was loaded onto a 2 cm C18 trap column on an LC-20AD nanoHPLC (Shimadzu, Kyoto, Japan), and then eluted onto a 10 cm analytical C18 column (inner diameter 75 μm). The samples were loaded at 8 μL/min for 4 min, then the gradients run: 300 nL/min for 44 min in 2--35% solvent B (98% acetonitrile, 0.1% formic acid), linear gradient to 80% solvent B for 2 min, and maintained in 80% solvent B for 4 min, and finally returned to 5% in 1 min. Tandem mass spectrometry (MS/MS) was performed with Q EXACTIVE (Thermo Fisher Scientific, San Jose, CA) coupled online to the HPLC, following nanoelectrospray ionization. Intact peptides were detected in the Orbitrap at a resolution of 70,000. Peptides were selected for MS/MS using high-energy collision dissociation (HCD) operating mode with a normalized collision energy setting of 27.0 (±12%); ion fragments were detected in the Orbitrap at a resolution of 17,500. A data-dependent procedure that alternated between one MS scan followed by 15 MS/MS scans was applied for the 15 most abundant precursor ions above a threshold ion count of 20,000 in the MS survey scan with a following Dynamic Exclusion duration of 15 s. The electrospray voltage was set to 1.6 kV. Automatic gain control (AGC) was used to optimize the spectra generated by the Orbitrap and the AGC target for full MS was 3e6 and 1e5 for MS/MS. The *m/z* scan range of 350--2,000 Da for MS scan, and 100--1,800 Da for MS/MS scan.

Bioinformatics analysis {#Sec13}
-----------------------

Raw data files generated from the LC-MS/MS were converted into MGF files using 5600 msconverter, and the MGF files were searched. Proteins were identified using Mascot search engine (Matrix Science, London, UK; version 2.3.02) against Uniprot homo database. The search criteria for protein identification were a mass tolerance of 20 ppm for intact peptide masses, and 0.05 Da for fragmented ions. Only one missed cleavage was allowed. Gln → pyro-Glu (N-term Q), oxidation (M), deamidated (NQ) and carbamidomethyl (C), iTRAQ8plex (N-term), iTRAQ8plex (K) were chosen as the potential variable modifications and fixed modifications, respectively. The charge states of peptides were set to +2 and +3. Specifically, an automatic decoy database search was performed in Mascot by choosing the decoy checkbox in which a random sequence of database was generated and tested for raw spectra as well as the real database^[@CR49]^. To reduce false positive results, all data were reported based on a 95% confidence and false discovery rate (FDR) less than 1%. All the confident protein identifications involve at least one unique peptide. The quantitative protein ratios were weighted and normalized by the median ratio in Mascot. All the results of quantitative proteins were then exported into Microsoft Excel software (14.4.9) for manual data interpretation. To fully identify the proteins regulated by Leu deprivation, we used two kinds of criteria to consider the differential expressions of proteins as follows: 1) for the proteins quantified in both the two sets of iTRAQ experiments, the differentially expressed proteins were defined by criteria of unique peptide \>1, *P*-value \< 0.05, fold change \>1.2 (or \<0.833) in both the two iTRAQ experiments^[@CR50]--[@CR52]^; 2) for the proteins quantified in only one set of iTRAQ experiment, the differentially expressed proteins were defined by criteria of unique peptide \>1, *P*-value \< 0.05, fold change \>2 (or \<0.5) in any one set of the two iTRAQ experiments^[@CR19],\ [@CR21]^.

Gene Ontology (GO) analysis was performed using Blast2GO program. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (<http://www.genome.jp/kegg/>) was used to study the amino acid metabolism and display the detail of fatty acid degradation pathway. Functional characterization, interaction network and pathway analysis were conducted using Ingenuity Pathway Analysis (IPA) software ([www.ingenuity.com](http://www.ingenuity.com)).

Immunoblotting assays {#Sec14}
---------------------

HepG2 cells were lysed using lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with protease inhibitors (1 μg/mL Leupeptin, 1 μg/mL Aprotinin, 1 μg/mL Pepstatin, and 50 μg/mL PMSF). Equal amounts of cell lysates were resolved by 10% SDS-PAGE. Proteins were then transferred onto PVDF membranes (16916600, Roche), blocked with 5% non-fat milk in Tris-buffered saline containing 0.05% Tween 20 for 1 hour, and probed with primary antibodies against ADH1C (A8081, ABclonal Technology), ALDH1A1 (A1802, ABclonal Technology), ACSL1 (A1000, ABclonal Technology), ACOX1 (A8091, ABclonal Technology), ACADS (A0945, ABclonal Technology), and β-Actin (4967L, Cell Signaling Technology). The specific proteins were detected with HRP-conjugated secondary antibodies (sc-2004, Santa Cruz Biotechnology), developed with SuperSignal West Pico Chemiluminescent Substrate (34080, Thermo Scientific) and visualized by Kodak Image Station 2000 MM. Immunoblotting results were quantified using Image J software (1.49s). All the immunoblotting assays were performed in three biological replicates.

Lipid accumulation and content measurements {#Sec15}
-------------------------------------------

Cellular lipid accumulation quantification was performed by Oil Red O (ORO) staining. In detail, HepG2 cells were cultured overnight in 6-well culture plates. Cell media were then replaced with fresh normal and Leu-deprived media, respectively. Cells were cultured for 24 h at 37 °C under 5% CO~2~. Cells were then fixed in 4% paraformaldehyde for 30 min, washed three times with PBS and stained with pre-warmed diluted ORO solution (O1391, Sigma-Aldrich) for 1 h in darkness. The droplets were observed with light microscope (CKX31, Olympus). Cellular TG content was measured with the Triglyceride Assay Kit (A110-1, Nanjing Jiancheng Bioengineering Institute, China) following the manufacturer's instructions. The measurements were performed in six biological replicates.

Statistical analysis {#Sec16}
--------------------

All statistical analyses for immunoblotting assays and the lipid accumulation and content measurements were performed using GraphPad Prism software (6.0c). Values are shown as mean ± standard deviation (SD), and statistical significance was calculated using two-tailed Student's *t*-test. Differences were considered statistically significant at *P* \< 0.05.
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